Periprocedural creatine kinase-MB elevations: Long-term impact and clinical implications

Clinical Cardiology

Volumn 22, Issue 4, 1999, Pages 257-265

  Adgey, A A Jennifer ^a   Mathew, T P ^a   Harbinson, M T ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Coronary intervention; Creatine kinase; Creatine kinase MB; Glycoprotein IIb IIIa inhibitor; Non Q wave myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ATHERECTOMY; CORONARY STENT; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFICACY; HEART INFARCTION; HEART PROTECTION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; PROGNOSIS; REVIEW; RISK FACTOR; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0032926217     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960220403     Document Type: Review

References (50)

1. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel M: A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495
2. Topol EJ, Leya F, Pinkerton CA, Whitlow P, Hofling B, Simonton C, Masden R, Serruys P, Leon M, Williams D, King S, Mark D, Isner J, Holmes D, Ellis S, Lee K, Keeler G, Berdan L, Hinohara T, Califf R: A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. N Engl J Med 1993;329:221-227
3. Fischman DL, Leon MB, Baim DS, Schatz R, Savage M, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein P, Fish D, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S: A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501
4. Baim DS, Cutlip DE, Sharma SK, Ho KKL, Fortuna R, Schreiber TL, Feldman RL, Shani J, Senerchia C, Zhang Y, Lansky AJ, Popma JJ, Kuntz RE: Final results of the Balloon vs Optimal Atherectomy Trial (BOAT). Circulation 1998;97:322-331
5. Pasternak RC, Braunwald E: Acute myocardial infarction. In Harrison's Principles of Internal Medicine, 13th ed. (Eds. Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL), p. 1066-1077. New York: McGraw-Hill, 1994
6. Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ, Lipicky RJ, Granger CB, Harrington RA, Tardiff BE, Crenshaw BS, Bauman RP, Zuckerman BD, Chaitman BR, Bittl JA, Ohman EM: Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-251
7. Pauletto P, Piccolo D, Scannapieco G, Vescovo G, Zaninotto M, Corbara F, Cuman G, Chioin R, Casiglia E, Maddalena F, Pessina AC, Dal Palu C: Changes in myoglobin, creatine kinase and creatine kinase-MB after percutaneous transluminal coronary angioplasty for stable angina pectoris. Am J Cardiol 1987;59:999-1000
8. Ishikawa Y, Saffitz JE, Mealman TL, Grace AM, Roberts R: Reversible myocardial ischemic injury is not associated with increased creatine kinase activity in plasma. Clin Chem 1997;43: 467-175
9. Abdelmeguid AE, Ellis SG, Sapp SK, Whitlow PL, Topol EJ: Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J 1996;131: 1097-1105
10. Weaver WD, Ross AM, Yakubov SJ, Deckelbaum LI, Midwall J: The reduction in rate of peri-angioplasty myocardial infarction after treatment with IIb/IIIa receptor antagonists is dependent on MI definition (abstr947-85). J Am Coll Cardiol 1997;29(suppl A): 241A
11. Rupprecht H-J, Terres W, Özbek CE, Luz M, Jessel A, Hafner G, Vom Dahl J, Kromer EP, Prellwitz W, Meyer J: Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina. J Am Coll Cardiol 1995;26:1637-1642
12. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E: Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl Med 1996;335:1342-1349
13. Garcia E, Serruys PW, Dawkins K, Hanet C, Rutsch W, te Riele H, Crean P, Hopp H, Materne P, Binhaghi G: BENESTENT-II Trial: Final results of visit II & III: A 7-month follow-up(abstr 1960). Eur Heart J 1997;18:350
14. Bhalla HS, Topol EJ: Non QMI post percutaneous coronary revasculurization is underreported unless there is systematic collection of enzymatic data (abstr 0290). Circulation 1996;94(suppl I):I-51
15. Ferguson JJ, Fox R: Meeting highlights. Circulation 1997;95: 761-764
16. Elliott JM, Berdan LG, Holmes DR, Isner JM, King SB, Keeler GP, Kearney M, Califf RM, Topol EJ: One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT 1). Circulation 1995;91:2158-2166
17. Holmes DR, Topol EJ, Califf RM, Berdan LG, Leya F, Berger PB, Whitlow PL, Safian RD, Adelman AG, Kellett MA, Talley D, Shani J, Gottlieb RS, Pinkerton CA, Lee KL, Keeler GP, Ellis SG: A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. Circulation 1995;91:1966-1974
18. Lefkovits J, Holmes DR, Califf RM, Safian RD, Pieper K, Keeler G, Topol ED: Predictors and sequelae of distal embolization during saphenous vein graft intervention from the CAVEAT-II trial. Circulation 1995;92:734-740
19. Lefkovits J, Blankenship JC, Anderson KM, Stoner GL, Talley D, Worley SJ, Weisman HF, Califf RM, Topol EJ: Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: Evidence from the EPIC trial. J Am Coll Cardiol 1996;28:849-855
20. Bertrand ME, Lablanche JM, Leroy F, Bauters C, De Jaegere P, Serruys PW, Meyer J, Dietz U, Erbel R: Percutaneous transluminal coronary rotary ablation with Rotablator (European experience). Am J Cardiol 1992;69:470-474
21. Warth DC, Leon MB, O'Neill W, Zacca N, Polissar NL, Buchbinder M: Rotational atherectomy multicenter registry: Acute results, complications and 6-month angiographic follow-up in 709 patients. J Am Coll Cardiol 1994;24:641-648
22. MacIsaac AI, Bass TA, Buchbinder M, Cowley MJ, Leon MB, Warth DC, Whitlow PL: High speed rotational atherectomy: Outcome in calcified and noncalcified coronary artery lesions. J Am Coll Cardiol 1995;26:731-736
23. Teirstein PS, Warth DC, Haq N, Jenkins NS, McCowen LC, Aubanel-Reidel P, Morris N, Ginsburg R: High speed rotational coronary atherectomy for patients with diffuse coronary artery disease. J Am Coll Cardiol 1991;18:1694-1701
24. Braden GA, Love WM, Applegate RJ, Young TM, Sane DC: Abciximab decreases the incidence and magnitude of non-Q wave myocardial infarction associated with rotational atherectomy (abstr 1088-102). J Am Coll Cardiol 1998;31(suppl A):237A-238A
25. Ohman EM, Tardiff BE: Periprocedural cardiac marker elevation after percutaneous coronary artery revascularization: Importance and implications. J Am Med Assoc 1997;277:495-497
26. Harrington RA, Lincoff AM, Califf RM, Holmes DR, Berdan LG, O'Hanesian MA, Keeler GP, Garratt KN, Ohman EM, Mark DB, Jacobs AK, Topol EJ: Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: Insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol 1995;25:1693-1699
27. Abdelmeguid AE, Whitlow PL, Sapp SK, Ellis SG, Topol EJ: Long-term outcome of transient, uncomplicated in-laboratory coronary artery closure. Circulation 1995;91:2733-2741
28. Redwood SR, Popma JJ, Kent KM, Pichard AD, Satler LF, Hong MK, Chuang YC, Clark CE, Bucher TA, MacKenzie J, Leon MB: "Minor" CPK-MB elevations are associated with increased late mortality follow ing ablative new-device angioplasty in native coronary arteries (abstr 2600). Circulation 1995;92(suppl I):1-544
29. Simoons ML, Harrington R, Lincoff M, Anderson K, Deckers JW, Zelinger D, Hoynck van Papendrecht M, Califf R, Topol EJ: Impaired prognosis after small, non-Q myocardial infarction during PTCA. Eur Heart J 1997;18(suppl):132
30. Kong TQ Jr, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO: Prognostic implication of creatine kinase elevation following elective coronary artery interventions. J Am Med Assoc 1997;277:461-466
31. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG: Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94: 1528-1536
32. 3 blockade with percutaneous coronary intervention. J Am Med Assoc 1997;278:479-484
33. The IMPACT-II Investigators: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-1428
34. Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KM, Harrington RA, Mahaffey KW, Teirstein P, Heinsimer J, Topol EJ: Post-intervention cardiac enzyme elevations: Prognostic significance in IMPACT II (abstr 903-5).J Am Coll Canliol 1996;27(suppl A):83A
35. Ghazzal Z, Chalasani P, Shen Y, Chronos N, King SB III, Weintraub WS: Does the magnitude of creatine kinase elevation impact survival in non-Q myocardial infarction after coronary interventions? (abstr 860-3). J Am Coll Cardiol 1998;31(suppl A): 215A-216A
36. Saucedo JF, Popma JJ, Mehran R, Bucher T, Abizaid AS, Curran M, Mastoor M, Kent KM, Pichard A, Satler L, Leon MB: Lack of association of intermediate CPK-MB elevation and late mortality in patients treated with intracoronary stents (abstr 860-1). J Am Coll Cardiol 1998;31(suppl A):215A
37. Sharma SK, Kini A, Kini S, Vidhun R, Dangas G, Duvvuri S, Cocke TP, Ambrose JA, Marmur JD: Incidence of creatinine kinase-MB enzyme elevation after coronary intervention: Correlation with device type and coronary anatomy (abstr TCT-76). Am J Cardiol 1997;80(suppl):23S
38. Fuster V, Jang I-K: Role of platelet-inhibitor agents in coronary artery disease. In Textbook of Interventional Cardiology (Ed. Topol EJ), p. 3-22. Philadelphia, Pa: W.B. Saunders, 1994
39. Fischman DL, Savage MP: The platelet, the patient, and periprocedural infarction during percutaneous transluminal coronary angioplasty. J Am Med Assoc 1997;278:518-519
40. Liu MW, Douglas JS, Lembo NJ, King SB III: Angiographic predictors of a rise in serum creatine kinase (distal embolization) after balloon angioplasty of saphenous vein coronary artery bypass grafts. Am J Cardiol 1993;72:514-517
41. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961
42. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696
43. The CAPTURE Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349: 1429-1435
44. Blankenship JC, Sigmon KN, Tardiff BE, Demko SL, Tcheng JE: Effect of glycoprotein IIb/IIIa receptor inhibition on specific in-lab complications of coronary intervention and resultant CKMB elevation in the IMPACT II trial (abstr 1150). Circulation 1996;94(suppl I):I-198
45. Kereiakes D, Cabot K, Melsheimer RM, Lincoff AM, Califf RM, Topol EJ: Abciximab-mediated platelet GPIIb/IIIa blockade improves outcomes following multiple interventional technologies: Results of the EPILOG trial (abstr TCT-29). Am J Cardiol 1997; 80(suppl):9S
46. Braden GA, Applegate RJ, Young TM, Love WW, Sane DC: Abciximab decreases both the incidence and magnitude of creatine kinase elevation during rotational atherectomy (abstr 1082-7). J Am Coll Cardiol 1997;29(suppl A):499A
47. Buchbinder MA, Braden GA, Sharma SK, Harms V, Reisman M: A pilot study of ReoPro with rotational atherectomy (RA) to reduce creatine kinase (CK) elevation post procedure (abstr 1147). Circulation 1996;94(suppl I):I-197
48. Kereiakes DJ, Lincoff AM, Simoons ML, deBoer MJ, Tcheng JE, Vahanian A, Anderson KM, Weisman HF, Califf RA, Topol EJ: Complementarity of stenting and abciximab for percutaneous coronary intervention (abstr 802-2). J Am Coll Cardiol 1998; 31(suppl A):54A
49. The EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92
50. Challapalli RM, Eisenberg MJ, Sigmon K, Lemberger J: Platelet glycoprotein IIb/IIIa monoclonal antibody (c7E3) reduces distal embolization during percutaneous intervention of saphenous vein grafts (abstr 2908). Circulation 1995;92(suppl I):I-607